ReShape Lifesciences prices public stock offering

ReShape Lifesciences Inc. (NASDAQ:RSLS), a pharmaceutical company incorporated in Delaware, announced today the pricing of its public offering of common stock. The company is offering 1,054,604 shares at a price of $2.50 per share, aiming to raise gross proceeds of approximately $2.63 million before deducting placement agent fees and other related expenses. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a current ratio of 1.53, though it faces profitability challenges with negative earnings in the last twelve months.

This offering is part of a larger at-the-market public offering (ATM Offering) that was previously disclosed on May 30, 2025. ReShape Lifesciences had entered into an Equity Distribution Agreement with Maxim Group LLC to sell up to $9.7 million of its common stock. Since the commencement of the ATM Offering, ReShape Lifesciences has sold shares totaling $3.64 million. Following the current public offering, the remaining amount available under the ATM Offering will be approximately $3.42 million. With a market capitalization of just $1.77 million and annual revenue of $7.17 million, the company’s fundraising efforts come at a crucial time. InvestingPro analysis suggests the stock is currently undervalued, with 13 additional key insights available to subscribers.

The shares are being offered pursuant to an effective shelf registration statement, including a related prospectus, previously filed with the Securities and Exchange Commission (SEC). The current report on Form 8-K, however, does not constitute an offer to sell or the solicitation of an offer to buy any securities.

ReShape Lifesciences, formerly known as Obalon Therapeutics (NASDAQ:OBLN_old) Inc., specializes in pharmaceutical preparations and is headquartered in Irvine, California. The company’s common stock is listed on the Nasdaq Capital Market under the trading symbol RSLS.

The information reported is based on a press release statement and reflects the company’s latest financial activities and strategic efforts to raise capital through equity offerings.

In other recent news, ReShape Lifesciences has announced the pricing of a public stock offering, with 1,054,604 shares set at $2.50 each, aiming to raise approximately $2.6 million. The offering is expected to close soon, with Maxim Group LLC as the sole placement agent. Additionally, ReShape Lifesciences has achieved certification under the EU Medical (TASE:BLWV) Device Regulation and UK Conformity Assessment, ensuring its products meet stringent safety and quality standards in Europe and the UK. The company is also progressing with its merger with Vyome Therapeutics, as detailed in a recent 8-K filing with the SEC, which includes financial statements and management discussions. Furthermore, ReShape has announced a 1-for-25 reverse stock split, consolidating shares to manage its stock structure effectively. In other developments, the company presented promising pre-clinical data on its Diabetes Neuromodulation device, which modulates glucose levels without cardiac side effects. Lastly, ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., to sell most of its assets, including the Lap-Band System and Obalon Gastric Balloon System.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.